Copyright: Shenzhen Kangtai biological products Limited by Share Ltd Address: No. 6, KORUN Road, Nanshan District science and Technology Park, Shenzhen Tel：86-755-26988688
粤ICP备06026377号 Fax：86-755-26988600 E-mail：office@biokangtai.com Hotline：400-880-6992 Powered by www.300.cn
|
1992
|
Company establishment
|
|
1995 |
5 μg/0.5ml/standard hepatitis B vaccine meets Merck's quality standards |
|
|
Obtaining the Ministry of Health trial production approval number
|
|
1998
|
Obtained the official approval number from the State Food and Drug Administration
|
|
2000
|
Hepatitis B vaccine passed GMP certification for the first time
|
|
2002
|
Successfully Developed 10 μg/1.0ml/Standard Hepatitis B Vaccine for Adults
|
|
2004
|
Successfully developed the first three-year hepatitis B vaccine in China
|
|
2005 |
Add 10μg/0.5ml/piece of standard hepatitis B vaccine for adults, replacing 10μg/1.0ml/piece size |
|
|
Hepatitis B vaccine passed GMP certification for the second time
|
|
2008
|
After the strategic reorganization, Beijing Minhai Biotechnology Co., Ltd. became a wholly-owned subsidiary of Kangtai Biotechnology
|
|
2010 |
First domestically developed 60μg/1.0ml/counter hepatitis B vaccine for adult non-response population |
|
|
Hepatitis B vaccine passed GMP certification for the third time |
|
2011 |
Successfully developed adult 20μg/1.0ml/support hepatitis B vaccine |
|
|
Successfully developed 10g/0.5ml/standard hepatitis B vaccine for children
|
|
2012 |
Haemophilus influenzae type b conjugate vaccine passed GMP certification |
|
|
Acellular Baidubai Haemophilus influenzae combined vaccine passed GMP certification
|
|
2013
|
Measles Rubella Combined with Live Attenuated Vaccine Passes GMP Certification
|
|
2014 |
Hepatitis B vaccine passed the 2010 version of GMP certification |
|
|
Haemophilus influenzae type b conjugate vaccine (pre-filled) passed GMP certification
|
|
2017 |
The company is listed on the GEM of Shenzhen Stock Exchange, stock code 300601 |
| 2018 | In October, Kangtai Guangming base was officially put into use |
| 2019 | 23-Valent Pneumonia Vaccine received lot release and was officially launched into market |
| 2020 |
Start construction of COVID-19 inactivated vaccine production workshop in Nanshan district,Shenzhen; Signs deal with AstraZeneca on development and industrialization of a COVID-19 vaccine based on adenovirus vector |